May 12, 2026 7:00 am EDT Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
May 7, 2026 4:01 pm EDT Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Apr 30, 2026 4:01 pm EDT Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Apr 22, 2026 4:15 pm EDT Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
Apr 18, 2026 7:38 pm EDT Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Apr 9, 2026 7:00 am EDT Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Mar 31, 2026 7:00 am EDT New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States